The extended-release formulation is relevant for the treatment of panic disorder, including with or without agoraphobia, a condition characterized by recurrent unexpected panic attacks.

This medication is commonly used to help manage conditions characterized by periods of heightened symptoms such as Panic Disorder and Generalized Anxiety Disorder (GAD). It is applied across therapeutic domains where additional symptomatic support is needed for relief from symptoms that interfere with daily functioning.

Its use is relevant for easing symptoms related to heightened physiological activity that appear suddenly (like a pounding heart and chest discomfort) and for helping to address the chronic pattern of uncontrollable worry and pervasive tension. This supportive relief plays a role in managing the overall symptomatic burden of these highly distressing episodes.

“The sustained-release profile is helpful in situations requiring consistent neurological stabilization to assist with maintaining functional stability.”

---

Quick Fact: Relief for Pathological Tension

The extended-release design of Xanor XR supports functional stability by offering symptomatic relief that helps patients cope more steadily with symptom fluctuations across a prolonged duration, assisting with maintaining functional stability during symptomatic periods.

Eligibility Map: Who Can and Cannot Use Xanor XR — Official Regulatory Information

The eligibility profile for Xanor XR (alprazolam extended-release) is strictly defined by regulatory documents, allowing use in adults for the treatment of panic disorder. Use is formally contraindicated in several populations.

Eligibility Scope	Official Regulatory Status
Populations Contraindicated	Hypersensitivity to alprazolam or other benzodiazepines; acute narrow-angle glaucoma; use with strong CYP3A inhibitors (e.g., ketoconazole, itraconazole); severe hepatic or respiratory insufficiency.
Age-Group Eligibility	Adults are eligible. Safety and efficacy have not been established in pediatric patients (under 18 years), and use is not recommended.
Conditional/Restricted Use	Geriatric patients may be sensitive to the drug's effects. Caution is required for use in patients with hepatic impairment, renal impairment, pre-existing respiratory issues, or depression.
Pregnancy/Lactation Status	Use during pregnancy is associated with risks like Neonatal Sedation and Neonatal Withdrawal Syndrome (NOWS). Use during lactation is advised against due to potential adverse effects on the infant.

Connection to the Overall Eligibility Profile: Official labeling establishes eligibility by outlining specific absolute prohibitions (contraindications) related to allergies, concomitant medications, and severe comorbidities. For populations requiring additional clinical monitoring, such as the elderly or those with impaired organ function, the regulatory documents mandate conditional use and caution rather than absolute exclusion.

Interactions with other medicines and products

Xanor XR (alprazolam) interacts with other substances primarily through two mechanisms: additive Central Nervous System (CNS) depressant effects and alterations in its metabolic clearance.

Clinically Significant Drug Interactions

Interacting Product Category	Effect on Xanor XR / Associated Risk	Classification
Opioids	Increased risk of profound sedation, respiratory depression, coma, and death.	Boxed Warning
Strong CYP3A Inhibitors (e.g., ketoconazole, itraconazole)	Significantly increased plasma concentrations of alprazolam.	Contraindicated (except ritonavir)
Other CNS Depressants (including alcohol)	Additive CNS depressant effects, leading to increased sedation and impaired performance.	Avoid or Use with Caution
CYP3A Inducers (e.g., carbamazepine)	Decreased plasma concentrations of alprazolam, potentially reducing efficacy.	Use with Caution
Digoxin	Increased risk of digoxin toxicity.	Use with Caution

Mechanism of Interaction

Alprazolam is primarily metabolized by the Cytochrome P450 3A (CYP3A) enzyme system. Inhibitors of CYP3A decrease alprazolam breakdown, leading to elevated levels and increased risk of adverse effects. Conversely, inducers of CYP3A increase alprazolam breakdown, potentially resulting in subtherapeutic drug levels.

Concomitant use with alcohol or other CNS depressants results in a combined depression of the central nervous system.

How Xanor XR Works: Pharmacodynamic Mechanism

Xanor XR (alprazolam) operates through the allosteric potentiation of inhibitory GABA A receptors, which are principally located in the central nervous system (CNS). This action increases the inhibitory tone within relevant neural networks.

---

Allosteric Potentiation of GABA A Receptors

The drug's primary action involves specific GABA-A receptor subunits, particularly those associated with rapid neuronal signaling. The binding of Xanor XR to a specific allosteric site on the GABA A receptor complex promotes the affinity of the receptor for GABA, which subsequently facilitates the opening of the associated chloride ion ( Cl^-) channel. This results in hyperpolarization of the neuronal membrane, which increases the threshold required for action potential generation.

---

Reduction of Action Potential Frequency

This action is the primary downstream effect of potentiated GABA-ergic transmission on broader neuronal circuits. By strengthening GABA's inhibitory actions, the drug modulates key pathways associated with rapid and sustained cellular signaling in areas like the limbic system. This inhibitory action reduces neuronal membrane excitability, resulting in a decreased frequency of action potentials in targeted neural circuits.

Administration Guidelines: Xanor XR

Xanor XR (alprazolam extended-release) is administered orally, as a tablet taken once daily, preferably in the morning. The tablet must be swallowed whole with water and should not be divided, crushed, or chewed.

---

Dosing and Adjustment Rules

Administration Scope	General Specification
Route of Administration	Oral
Recommended Starting Dose	0.5 mg to 1 mg once daily
Recommended Daily Range	3 mg to 6 mg once daily (maximum of 10 mg/day for occasional patients)
Dose Increase Protocol	Increase the dose at intervals of 3 to 4 days in increments of no more than 1 mg daily
Geriatric Starting Dose	0.5 mg once daily; increase gradually as needed and tolerated

---

Procedural Conditions

• Timing: Take the dose once daily, preferably in the morning. Food can influence the drug's absorption, with a high-fat meal taken up to two hours before dosing potentially increasing maximum concentration.
• Missed Dose: If a dose is missed, take it as soon as it is remembered. However, if it is almost time for the next scheduled dose, skip the missed dose. Do not take a double dose.
• Discontinuation/Tapering: To minimize withdrawal reactions, the dosage must be reduced gradually. Decrease the dosage by no more than 0.5 mg every 3 days; some patients may require an even slower reduction schedule.

Research Evidence / Overview of Studies for Xanor XR

---

Evidence for use in Panic Disorder

Research exploring Xanor XR (alprazolam extended-release) for panic disorder has primarily relied on short-term, randomized, double-blind, placebo-controlled trials (RCTs) and open-label studies. These studies were used in research exploring how symptoms change over time by monitoring changes in the frequency and intensity of panic attacks, as well as outcomes reflecting daily functioning or activity level. Studies generally included adults diagnosed with panic disorder, whether or not they also experienced agoraphobia.

While short-term research contributes to the broader evidence landscape, long-term effects are not fully established. Follow-up durations were limited in the primary controlled trials, meaning the long-term effects are not fully established. Additionally, there is limited information for long-term outcomes and how symptom intensity or variability may evolve over many months or years of use.

---

Comparisons with Placebo and Other Treatments

Studies conducted during periods of increased symptom activity were designed to measure the measured changes in patients receiving Xanor XR, and examined measurements recorded in patients receiving Xanor XR for comparison with those receiving a placebo (an inactive substance). Findings included comparisons of patient-reported outcomes describing perceived discomfort recorded between the two groups over the defined time intervals.

Furthermore, research examined Xanor XR against other active treatments, including the immediate-release form of alprazolam. These studies examined whether the different formulations recorded similar or varied patterns of symptom measurements. Research provides context on these comparisons, but study results reflect the specific conditions under which they were conducted and research does not provide individual predictions about whether a patient will respond similarly to one over the other.

---

Long-Term Studies and Follow-Up

The research base for Xanor XR primarily includes findings from short-term controlled studies. While some subsequent open-label studies have observed responses over defined time intervals extending up to several months, the evidence for use beyond the initial few months remains limited. Research explored how symptoms change over time in these studies, examining how patients fared when symptoms may vary in intensity.

---

Evidence in Special Populations and Subgroups

The available evidence primarily reflects findings from the adult population studied in the initial randomized controlled trials. Data for certain groups remain insufficient, especially for special populations like adolescents and pregnant-related populations, where studies focusing on episodes where symptoms become more noticeable are generally lacking or absent. Research has explored the use of Xanor XR in older adults, and these studies were applied in research examining patient-reported experiences in this specific age group.

---

Research Quality and Areas of Uncertainty

The body of evidence for Xanor XR includes randomized, controlled research designs, but the evidence quality varies across studies, and findings were mixed in some contexts. Key research limitations include that follow-up durations were limited, meaning the long-term effects are not fully established. Head-to-head comparative research examining Xanor XR against other medication classes is also an area where data are still emerging.

Key Studies & References

1. The Efficacy and Safety of Alprazolam Versus Other Benzodiazepines in the Treatment of Panic Disorder - Journal of Clinical Psychopharmacology

Common questions about Xanor XR (FAQ)

Q: What is the controlled substance classification of Xanor XR?

According to regulatory documents in the United States, Xanor XR (alprazolam extended-release) is classified as a Schedule IV controlled substance. This classification indicates that the drug has an accepted medical use but also carries a potential for abuse and dependence, which is one of the reasons for its regulatory oversight.

Q: How long does Xanor XR stay in the body or work for?

Official product information, based on pharmacokinetic studies in healthy adults, reports that the mean plasma elimination half-life of alprazolam extended-release ranges from approximately 10.7 to 15.8 hours. The extended-release formulation is designed to maintain a consistent concentration of the active ingredient, alprazolam, over a prolonged period.

Q: Is Xanor XR affected by birth control pills?

Regulatory information indicates that substances which inhibit the CYP3A4 enzyme are expected to increase the concentration of alprazolam in the body. Although oral contraceptives (birth control pills) are not always specifically listed in the drug interaction table, many hormonal contraceptives can affect the CYP3A4 enzyme. Because of the potential for this interaction, it is important for a healthcare provider to be aware of all medications being taken.

Q: What dosage strengths are available for Xanor XR?

Official regulatory labels indicate that alprazolam extended-release tablets are available in multiple dosage strengths. The tablets typically come in 0.5 mg, 1 mg, 2 mg, and 3 mg strengths. The availability of different strengths allows for the careful management of use based on a healthcare provider's evaluation.

Q: What are the common brand names for alprazolam extended-release tablets in the US?

The active ingredient is alprazolam, and Xanor XR is a specific brand name. In the United States, another common brand name for alprazolam extended-release tablets listed in regulatory filings is XANAX XR. The medication may also be available under its generic name, alprazolam extended-release.

Q: Can Xanor XR cause high or low blood pressure?

Official safety data indicates that hypotension (low blood pressure) has been reported as an adverse reaction. This finding was documented in clinical trials involving the immediate-release form of alprazolam. Because Xanor XR contains the same active ingredient, alprazolam, this effect is a documented adverse reaction reported with the immediate-release formulation.

Q: Does Xanor XR cause mood swings or confusion?

Official documentation reports that some patients taking alprazolam extended-release have experienced certain adverse events related to mental state. These reported events include depression, confusional state, and disorientation.

The storage and disposal of Xanor XR (alprazolam extended-release) tablets are strictly defined by regulatory requirements to ensure product quality and public safety.

Official Storage and Disposal Requirements

Labeled storage temperature requirements:	Store at Controlled Room Temperature, 20^circC to 25^circC (68^circF to 77^circF), with excursions permitted between 15^circC and 30^circC (59^circF and 86^circF).
Packaging-related storage rules:	Must be stored in a tight container and kept out of the reach and sight of children.
Disposal instructions:	Utilize an authorized drug take-back program. If a program is unavailable, the FDA mandates flushing the tablets down the toilet.

This mandatory disposal protocol is due to the high risk of serious harm or death from accidental ingestion, a risk that outweighs the minimal environmental concern. Storage must be maintained within the specified temperature range to ensure the product's stability and integrity.